O	0	10	Randomized
O	10	11	,
O	12	16	self
O	16	17	-
O	17	27	controlled
O	27	28	,
O	29	40	prospective
O	41	51	assessment
O	52	54	of
O	55	58	the
O	59	67	efficacy
O	68	70	of
B-intervention	71	81	mometasone
I-intervention	82	89	furoate
O	90	95	local
O	96	107	application
O	108	110	in
O	111	119	reducing
B-condition	120	125	acute
I-condition	126	135	radiation
I-condition	136	146	dermatitis
O	147	149	in
O	150	158	patients
O	159	163	with
O	164	168	head
O	169	172	and
O	173	177	neck
O	178	186	squamous
O	187	191	cell
O	192	202	carcinomas
O	202	203	.

O	204	209	Acute
O	210	219	radiation
O	220	230	dermatitis
O	231	232	(
O	232	235	ARD
O	235	236	)
O	237	239	is
O	240	241	a
O	242	248	common
O	249	256	adverse
O	257	263	effect
O	264	266	in
O	267	275	patients
O	276	286	undergoing
O	287	299	radiotherapy
O	299	300	.

O	301	311	Mometasone
O	312	319	furoate
O	320	325	cream
O	326	327	(
O	327	330	MMF
O	330	331	)
O	332	335	was
O	336	344	reported
O	345	347	to
O	348	361	significantly
O	362	368	reduce
O	369	372	ARD
O	372	373	,
O	374	384	especially
O	385	387	in
O	388	394	breast
O	395	401	cancer
O	401	402	.

O	403	413	Clinically
O	413	414	,
O	415	418	ARD
O	419	421	is
O	422	426	more
O	427	435	critical
O	436	439	and
O	440	444	more
O	445	454	difficult
O	455	457	to
O	458	465	prevent
O	466	468	in
O	469	477	patients
O	478	482	with
O	483	487	head
O	488	491	and
O	492	496	neck
O	497	505	squamous
O	506	510	cell
O	511	520	carcinoma
O	521	522	(
O	522	527	HNSCC
O	527	528	)
O	529	533	than
O	534	536	in
O	537	542	those
O	543	547	with
O	548	554	breast
O	555	561	cancer
O	561	562	,
O	563	570	because
O	571	572	a
O	573	579	higher
O	580	584	dose
O	585	587	of
O	588	600	radiotherapy
O	601	603	is
O	604	612	required
O	613	615	in
O	616	621	HNSCC
O	622	627	cases
O	627	628	.

O	629	632	The
O	633	636	aim
O	637	639	of
O	640	644	this
O	645	650	study
O	651	654	was
O	655	657	to
O	658	666	evaluate
O	667	670	the
O	671	677	effect
O	678	680	of
O	681	684	MMF
O	685	690	local
O	691	702	application
O	703	705	on
O	706	715	radiation
O	716	726	dermatitis
O	727	729	in
O	730	738	patients
O	739	743	with
O	744	749	HNSCC
O	749	750	.

B-eligibility	751	756	HNSCC
I-eligibility	757	765	patients
I-eligibility	766	775	scheduled
I-eligibility	776	779	for
I-eligibility	780	789	bilateral
I-eligibility	790	797	radical
I-eligibility	798	810	radiotherapy
I-eligibility	811	813	to
I-eligibility	814	817	the
I-eligibility	818	822	neck
I-eligibility	823	827	with
I-eligibility	828	837	identical
I-eligibility	838	847	radiation
I-eligibility	848	853	doses
O	854	858	were
O	859	867	enrolled
O	867	868	.

O	869	872	One
O	873	877	side
O	878	880	of
O	881	884	the
O	885	889	neck
O	890	894	skin
O	895	896	(
O	896	900	test
O	901	907	groups
O	907	908	)
O	909	911	of
O	912	915	the
O	916	924	patients
O	925	929	were
O	930	940	randomized
O	941	943	to
O	944	949	apply
O	950	951	a
O	952	956	thin
O	957	962	layer
O	963	965	of
O	966	969	MMF
O	970	974	once
O	975	976	a
O	977	980	day
O	981	985	from
O	986	989	the
O	990	994	date
O	995	997	of
O	998	1003	first
O	1004	1016	radiotherapy
O	1017	1022	until
O	1023	1029	either
O	1030	1031	2
O	1032	1037	weeks
O	1038	1043	after
O	1044	1047	end
O	1048	1050	of
O	1051	1063	radiotherapy
O	1064	1066	or
O	1067	1072	until
O	1073	1076	the
O	1077	1081	test
O	1082	1086	side
O	1087	1091	skin
O	1092	1101	developed
O	1102	1105	ARD
O	1106	1113	lesions
O	1113	1114	,
O	1115	1120	while
O	1121	1124	the
O	1125	1130	other
O	1131	1135	side
O	1136	1138	of
O	1139	1143	neck
O	1144	1145	(
B-control	1145	1152	control
I-control	1153	1159	groups
O	1159	1160	)
O	1161	1165	didn
O	1165	1166	'
O	1166	1167	t
O	1168	1173	apply
O	1174	1177	any
O	1178	1188	medication
O	1188	1189	.

O	1190	1193	The
O	1194	1202	severity
O	1203	1205	of
O	1206	1209	ARD
O	1210	1213	was
O	1214	1223	evaluated
O	1224	1230	weekly
O	1231	1233	by
O	1234	1239	using
O	1240	1243	the
O	1244	1252	modified
O	1253	1262	radiation
O	1263	1270	therapy
O	1271	1279	oncology
O	1280	1285	group
O	1286	1291	score
O	1291	1292	,
O	1293	1297	pain
O	1298	1307	intensity
O	1307	1308	,
O	1309	1312	and
O	1313	1317	itch
O	1318	1324	stages
O	1324	1325	.

B-total-participants	1326	1331	Forty
I-total-participants	1331	1332	-
I-total-participants	1332	1335	one
O	1336	1344	patients
O	1345	1346	(
O	1346	1348	82
O	1349	1356	targets
O	1356	1357	)
O	1358	1362	were
O	1363	1371	analyzed
O	1371	1372	.

O	1373	1378	There
O	1379	1382	was
O	1383	1384	a
O	1385	1396	significant
O	1397	1407	difference
O	1408	1415	between
O	1416	1419	the
B-outcome	1420	1423	ARD
I-outcome	1424	1430	scores
O	1431	1433	on
O	1434	1437	the
O	1438	1442	test
O	1443	1447	side
O	1448	1451	and
O	1452	1455	the
O	1456	1463	control
O	1464	1468	side
O	1468	1469	.

O	1470	1473	MMF
O	1474	1481	reduced
O	1482	1485	the
B-outcome	1486	1492	stages
I-outcome	1493	1495	of
I-outcome	1496	1499	ARD
O	1500	1504	when
O	1505	1508	the
O	1509	1521	radiotherapy
O	1522	1526	dose
O	1527	1530	was
O	1531	1532	<
O	1532	1536	6000
O	1537	1540	cGY
O	1541	1542	(
O	1542	1543	P
O	1544	1545	=
O	1546	1547	.
O	1547	1549	01
O	1549	1550	)
O	1551	1554	but
O	1555	1561	showed
O	1562	1564	no
O	1565	1576	improvement
O	1577	1581	when
O	1582	1585	the
O	1586	1590	dose
O	1591	1594	was
O	1595	1596	â‰¥
O	1596	1600	6000
O	1601	1604	cGY
O	1605	1606	(
O	1606	1607	P
O	1608	1609	=
O	1610	1611	.
O	1611	1614	699
O	1614	1615	)
O	1615	1616	.

O	1617	1625	Compared
O	1626	1628	to
O	1629	1632	the
O	1633	1640	control
O	1641	1645	side
O	1645	1646	,
O	1647	1652	local
O	1653	1664	application
O	1665	1667	of
O	1668	1671	MMF
O	1672	1685	significantly
O	1686	1693	reduced
O	1694	1697	the
B-outcome	1698	1702	itch
I-outcome	1703	1706	and
I-outcome	1707	1711	pain
I-outcome	1712	1718	scores
O	1719	1721	of
O	1722	1725	the
O	1726	1730	test
O	1731	1735	side
O	1736	1740	skin
O	1741	1751	regardless
O	1752	1754	of
O	1755	1758	the
O	1759	1771	radiotherapy
O	1772	1776	dose
O	1777	1780	and
O	1781	1784	ARD
O	1785	1790	stage
O	1791	1792	(
O	1792	1793	P
O	1794	1795	<
O	1796	1797	.
O	1797	1800	001
O	1800	1801	)
O	1802	1808	during
O	1809	1821	radiotherapy
O	1821	1822	.

O	1823	1827	This
O	1828	1833	study
O	1834	1840	showed
O	1841	1845	that
O	1846	1849	MMF
O	1850	1859	inunction
O	1860	1865	after
O	1866	1870	high
O	1870	1871	-
O	1871	1875	dose
O	1876	1888	radiotherapy
O	1889	1890	(
O	1890	1891	>
O	1891	1893	50
O	1894	1896	Gy
O	1896	1897	)
O	1898	1901	can
O	1902	1909	prevent
O	1910	1913	ARD
O	1913	1914	,
O	1915	1925	especially
O	1926	1930	when
O	1931	1934	the
O	1935	1944	radiation
O	1945	1949	dose
O	1950	1952	is
O	1953	1954	<
O	1954	1958	6000
O	1959	1962	cGY
O	1962	1963	.
